Subtype
Malignant Neck Neoplasm
CI-CAN-00001148Explore in graph →
607 active trials11 approved drugs67 evidence items
- NCIt
- C4940
Loading cancer entity…
Subtype
CI-CAN-00001148Explore in graph →
Clinical trials
2,145 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (181)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07628062 | Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation | not yet recruiting | Phase 2 | 70 | ImmunityBio, Inc.INDUSTRY | 0 | Jun 4, 2026 | clinicaltrials |
| NCT07618078 | Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC | recruiting | — | 900 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER |
| 1 |
| Jun 3, 2026 |
| clinicaltrials |
| NCT07621146 | A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies(NET-COMPARE) | not yet recruiting | — | 51 | British Columbia Cancer AgencyOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04825990 | Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer(POINT) | active not recruiting | Phase 2 | 30 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07068542 | Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer | recruiting | N/A | 94 | Zhejiang Provincial People's HospitalOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07584447 | Clinical Utility of Preoperative Thyroid GuidePx® Testing | not yet recruiting | — | 85 | University of CalgaryOTHER | 0 | Jun 1, 2026 | clinicaltrials |
| NCT05211232 | Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 450 | Sun Yat-sen UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT05145660 | Optimization of Cervical Nodal CTV for Early and Medium Stage NPC | active not recruiting | Phase 3 | 414 | Yi JunlinOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07612293 | STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection | not yet recruiting | N/A | 100 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT03039439 | Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors | recruiting | — | 310 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04589624 | An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy | recruiting | Phase 1 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05800574 | Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer | recruiting | Phase 2 | 22 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07325539 | LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC(LIGHT) | recruiting | Phase 2 | 55 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07603167 | p-PHOTOLARYNX- ANTHEM: Photon-Counting CT in Laryngeal Cancer Staging(H&NRAD-2025-01) | enrolling by invitation | — | 60 | Humanitas UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04759911 | Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07376837 | Radiofrequency Ablation for Curative Treatment of Small Low-Risk Papillary Thyroid Cancer: Pilot Study(PTC-RFA) | recruiting | N/A | 30 | University Health Network, TorontoOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT06234748 | Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer(ARTHOUSE) | active not recruiting | Phase 2 | 19 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07497607 | Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma(REDUCE-30) | recruiting | Phase 2 | 31 | Sara MedekOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06277050 | Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma | recruiting | Phase 3 | 264 | Jiangxi Provincial Cancer HospitalOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT01947023 | Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery | active not recruiting | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | May 14, 2026 | clinicaltrials |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | recruiting | Phase 1 | 11 | Brian Henick, MDOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07584499 | Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors(MRG003) | recruiting | Phase 1 | 51 | Sun Yat-sen UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT01704586 | I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer(CLERAD-PROBE) | active not recruiting | N/A | 340 | University of WuerzburgOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05420948 | A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer | recruiting | Phase 2 | 30 | University of ChicagoOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05541016 | De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA | recruiting | Phase 2 | 455 | Mayo ClinicOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06747390 | Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery(856397) | recruiting | Phase 1 | 30 | Ryan CareyOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06852638 | CD70-targeted immunoPET Imaging of Malignant Cancers | recruiting | Phase 2 | 300 | RenJi HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07581821 | Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma | recruiting | Phase 2 | 33 | Ming-Yuan ChenOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03930498 | Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 68 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04436965 | Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition | recruiting | Phase 3 | 266 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05340491 | Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial | recruiting | Phase 3 | 212 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05780372 | Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 474 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05941741 | IC Plus Low-dose Radiation Plus Cadonilimab in LANPC | recruiting | Phase 3 | 380 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06197776 | Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC | recruiting | — | 50 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06323239 | SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma | recruiting | Phase 2 | 148 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06802835 | EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma | recruiting | Phase 1 / Phase 2 | 148 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06984861 | A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer | recruiting | Phase 2 | 74 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06997068 | Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population | recruiting | Phase 2 | 25 | Mayo ClinicOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04425265 | Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma | recruiting | N/A | 500 | Sun Yat-sen UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05294172 | KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 295 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06682494 | Enhancing Oral Cancer Awareness | recruiting | N/A | 60 | Virginia Commonwealth UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT01398085 | IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients(IoN) | active not recruiting | Phase 2 / Phase 3 | 504 | University College, LondonOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT02609685 | Active Surveillance of Papillary Thyroid Microcarcinoma(PMCAS) | recruiting | N/A | 216 | Cedars-Sinai Medical CenterOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT03907826 | PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients | recruiting | Phase 3 | 212 | Sun Yat-sen UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04116047 | CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)(CompARE) | active not recruiting | Phase 3 | 785 | University of BirminghamOTHER | 2 | May 7, 2026 | clinicaltrials |
| NCT05201859 | Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 4, 2026source: clinicaltrials